Skip to main content

Branded

  • AJMC review: Formulary exclusions tend toward neutral, positive patient impacts

    PLAINSBORO, N.J. — A new review of several studies on the impact of drug exclusion from pharmacy benefits managers’s formularies has found that in most cases, these efforts to control costs work without negatively affecting patients. 
     

  • Fred’s makes naloxone available prescription-free in 5 states

    MEMPHIS, Tenn. — Fred’s Pharmacy announced Wednesday that it was joining the ranks of drug chains making overdose reversal medication naloxone available without a prescription. The company has partnered with prescribers in Alabama, Kentucky, Mississippi, North Carolina and Tennessee to make it possible for patients to obtain naloxone without having to first see a doctor. 
     

  • CVS Pharmacy locations now offering non-prescription naloxone in Idaho

    WOONSOCKET, R.I. - CVS Health announced Friday that the opioid overdose-reversal medication naloxone is now available without a prescription at CVS Pharmacy locations in Idaho. Under prescriptive authority allowed by the state, CVS Pharmacists will expand access to the medication.  

  • Study: Drug cost estimates trend higher than actual sales

    BEVERLY HILLS — Cost estimates put out before the launch of new drugs can often overestimate their impact on healthcare spending, according to a new study from research consultancy the Partnership for Health Analytics Research. 
     

  • Latest CDC study proves boomers benefit from flu shot

    ATLANTA - A new CDC study published Tuesday in the journal Clinical Infectious Diseases provides more evidence on the benefits of flu vaccination among older adults. The study looked at flu-associated hospitalizations among people 50 and older during the 2010-2011 flu season and found that people who had gotten a flu vaccine reduced their risk of flu-associated hospitalization by half.

  • Personalized solutions: Q&A with TopRx's Scott Franklin

    Scott Franklin, president of TopRx

  • Big-money meds lose patent protection in 2016

    Total spending on products whose patents expired between 2012 and 2015 declined by $14.2 billion last year, according to IMS Health’s Institute for Health Care informatics. And 2016 could bring about further cost reductions.

  • Companies fight to launch biosimilars amid expiries

    In April, the Food and Drug Administration granted approval to Pfizer’s Inflectra (infliximab) — a biosimilar of Janssen’s Remicade and possibly the second biosimilar to be launched in the United States. But like the first biosimilar, Zarxio (filgrastim-sndz), Inflectra is subject to a 180-day waiting period before launch, and is currently facing opposition from Janssen, which claims Remicade’s patent doesn’t expire until 2018.

X
This ad will auto-close in 10 seconds